Jeil Pharma Holdings제일파마홀딩스
002620 · KOSPI · ₩002620 · 제일파마홀딩스
₩6,900▲ ₩20 (0.29%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩658B | ₩780B | ₩804B | ₩793B | ₩763B |
| Cost of sales | ₩404B | ₩573B | ₩589B | ₩612B | ₩582B |
| Gross profit | ₩253B | ₩207B | ₩215B | ₩180B | ₩181B |
| Operating income | ₩39B | −₩12B | ₩21B | −₩7.5B | −₩9B |
| Net income | ₩35B | −₩66B | −₩13B | −₩83B | −₩13B |
| Net income to shareholders | ₩15B | −₩51B | −₩16B | −₩75B | −₩3.5B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩877B | ₩890B | ₩880B | ₩866B | ₩892B |
| Current assets | ₩373B | ₩410B | ₩385B | ₩353B | ₩335B |
| Cash and equivalents | ₩56B | ₩60B | ₩37B | ₩35B | ₩29B |
| Total liabilities | ₩408B | ₩453B | ₩478B | ₩446B | ₩392B |
| Current liabilities | ₩323B | ₩378B | ₩413B | ₩359B | ₩298B |
| Borrowings | ₩166B | ₩12B | ₩157B | ₩135B | ₩113B |
| Total equity | ₩469B | ₩437B | ₩402B | ₩420B | ₩500B |
| Shareholders' equity | ₩319B | ₩307B | ₩319B | ₩338B | ₩412B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩390M | ₩4.5B | −₩4.4B | −₩21B | ₩13B |
| Capital spending | ₩8.3B | ₩4.3B | ₩6.2B | ₩15B | ₩24B |
| Free cash flow | −₩7.9B | ₩202M | −₩11B | −₩36B | −₩10B |
| Dividends paid | ₩183M | ₩1.1B | ₩1.1B | ₩1.5B | ₩1.6B |
Consolidated where available. Amounts in won.
Also known as: Jeil Pharma Holdings / 제일파마홀딩스 / 002620 / KRX:002620
Source: KRX statistical information